姚春筱,张树平,陈保民.调强适形放疗联合替莫唑胺治疗恶性脑胶质瘤的临床观察[J].中国肿瘤,2013,22(3):238-240.
调强适形放疗联合替莫唑胺治疗恶性脑胶质瘤的临床观察
Clinical Effect of Intensity Modulated Radiation Therapy Combined with Concomitant and Adjuvant Temozolomide in the Treatment for Malignant Glioma
投稿时间:2013-01-09  
DOI:10.11735/j.issn.1004-0242.2013.03.A201301010
中文关键词:  恶性胶质瘤  调强适形放疗  替莫唑胺
英文关键词:malignant glioma  intensity modulated radiation therapy  temozolomide
基金项目:
作者单位
姚春筱 山西省人民医院 
张树平 山西省人民医院 
陈保民 山西省人民医院 
摘要点击次数: 1866
全文下载次数: 1021
中文摘要:
      摘 要:[目的] 观察调强适形放疗(IMRT)联合替莫唑胺(TMZ)治疗恶性脑胶质瘤的临床疗效。[方法] 28例术后病理诊断为高级别胶质瘤(WHO Ⅲ~Ⅳ)的患者,术后放射治疗为全脑左、右对穿野常规照射(WBRT)并后程调强加量照射。常规放射治疗剂量为40Gy/20f/4w,调强放射治疗剂量为20Gy/4f/2w;放疗同步口服替莫唑胺(TMZ) 治疗6个周期,之后再接受至少2个周期的常规TMZ治疗。[结果] 中位生存时间及无进展生存时间分别为11.5个月和7.2个月;1年总生存率为53.57%,2年总生存率为25.00%。常见的不良反应为恶心、呕吐,血液学毒性是白细胞和血小板下降,但仅限于Ⅰ~Ⅱ度。[结论] IMRT同步TMZ治疗恶性脑胶质瘤,安全有效,不良反应轻微。
英文摘要:
      Abstract:[Purpose] To investigate clinical efficacy of intensity modulated radiation therapy (IMRT) combined with concomitant and adjuvant temozolomide(TMZ) in the treatment for malignant glioma.[Methods] A total of 28 malignant glioma cases (grade Ⅲ~Ⅳ) pathologically proved were enrolled.After 40Gy/20f/4w by conventional fractionation irradiation delivered through whole brain left/right fields,IMRT was started as a boost.The irradiation dose of dose-escalation was 20Gy/4f/2w; TMZ was given for 6 cycles at the same time,then at least 2 cycles by the routine treatment.[Results] The median survival time and the progression free survival time were 11.5 months and 7.2 months respectively.1- year and 2- year survival rate were 53.57% and 25.00% respectively.The common side effects were nausea,vomiting; hematologic toxicity was white cells and platelets decreased(degreeⅠ~Ⅱ).[Conclusion] IMRT plus concomitant and adjuvant TMZ for malignant glioma is safe and effective,with mild adverse reactions.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器